Table 3 American College of Rheumatology Core Components and Acute Phase Reactants for Patients Identified as ACR20 Non-responders at Week 12
ACR Core Reactant | Components and Acute Phase | ACR20 Non-responder at Week 12 (N = 321/772, 41.6%) | |||
|---|---|---|---|---|---|
Baseline | Week 12 | Change | % Change | ||
ACR Core Set | Tender joint count (0-68 scale) | 14.4 ± 7.8 | 10.6 ± 7.9 | -3.8 ± 6.2 | -21.6 ± 57.3% |
Swollen joint count (0-66 scale) | 12.9 ± 5.2 | 9.1 ± 5.7 | -3.8 ± 5.0 | -28.1 ± 41.4% | |
Patient's assessment of pain, mm (0-100 mm VAS)a | 64.7 ± 24.3 | 55.3 ± 26.3 | -9.1 ± 25.1 | 7.1 ± 275% | |
Patient's global assessment of disease activity, mm (0-100 mm VAS)b | 64.6 ± 24.1 | 54.9 ± 26.6 | -9.5 ± 25.1 | 3.3 ± 191% | |
Physician's global assessment of disease activity, mm (0-100 mm VAS)b | 63.1 ± 17.8 | 42.7 ± 24.1 | -20.5 ± 23.0 | -31.1 ± 38.2% | |
HAQ-DI score (0-3 scale)c | 1.6 ± 0.6 | 1.4 ± 0.7 | -0.2 ± 0.4 | -14.7 ± 37.1% | |
Acute Phase Reactant | ESR (mm/h) normal value < 20 mm/h | 29.6 ± 23.7 | 23.5 ± 21.6 | -5.9 ± 15.8 | -9.2 ± 76.8% |